Skip to main content

Advertisement

SpringerLink
Log in

Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis

  • Short Communication
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

The treatment of drug-induced toxic epidermal necrolysis (TEN) remains unsatisfactory. Intravenous immunoglobulins (IVIg) and intravenous cyclosporin A (CsA) have shown some efficacy in short series of patients. We assessed the effects of IVIg and CsA on TEN lesional and apparently uninvolved skin using standard histology and immunohistochemistry. Cutaneous biopsies were taken from necrotic and clinically uninvolved TEN skin at admission (D1) before any treatment, and after a 5-day treatment (D5). Two IVIg-treated patients (0.75 g/kg/day), two CsA-treated patients (5 mg/kg/day) and two control patients only receiving supportive care were compared. Biopsies were examined by standard histology and immunohistochemistry using antibodies directed to CD68 antigen (macrophages), CD45R0 antigen (activated T lymphocytes), Factor XIIIa (dermal dendrocytes) and the CD95 receptor (apoptosis marker). The different cell densities were evaluated by computerized image analysis. The clinical outcomes with the different treatments were also recorded. There was no obvious difference in the duration of hospitalization in intensive care unit between the three groups but one patient passed away in each of the IVIg- and CsA-groups. At D5, no differences were found between the three groups in the histological and clinical rate of re-epithelialization, and in the evolution of T lymphocyte, macrophage and dendrocyte densities in the epidermis and dermis. However, the expression of the CD95 receptor was similarly and strongly abated at D5 in the epidermis of IVIg- and CsA-treated patients, while it was conversely increased in the two patients under supportive care only. Such a difference was found both in necrotic and uninvolved sites. IVIg and CsA treatments thus appeared to exert no obvious effect on the inflammatory infiltrate, but both abated the expression of the CD95 receptor in the skin of TEN patients. This effect did not seem sufficient to fully reverse the clinical evolution of the disease. It is inferred that IVIg and CsA do not completely abate the TEN process.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Arevalo J, Lorente JA, Gonzalez-Herrada C, Jimenez-Reyes J (2000) Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma Inj Inf Crit Care 48:473–478

    Article  CAS  Google Scholar 

  2. Bachot N, Revuz J, Roujeau JC (2003) Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 139:33–36

    Article  PubMed  CAS  Google Scholar 

  3. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P (2000) SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 45:149–153

    Article  Google Scholar 

  4. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC (1993) Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 129:92–96

    Article  PubMed  CAS  Google Scholar 

  5. Becker DS (1998) Toxic epidermal necrolysis. Lancet 351:1417–1420

    Article  PubMed  CAS  Google Scholar 

  6. Frangogiannis NG, Boridy F, Mazhar M, Mathews R, Gangopadhyay S, Cate T (1996) Cyclophosphamide in the treatment of toxic epidermal necrolysis. South Med J 89:1001–1003

    Article  PubMed  CAS  Google Scholar 

  7. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM (1997) The CD95 (APO-1Fas) system mediates drug-induces apoptosis in neuroblastoma cells. Cancer Res 57:3823–3829

    PubMed  CAS  Google Scholar 

  8. Herndon D (1995) Toxic epidermal necrolysis: a systemic and dermatologic disorder best treated with standard treatment protocols in burns intensive care units without the prolonged use of corticosteroids. J Am Coll Surg 180:340–342

    PubMed  CAS  Google Scholar 

  9. Jarrett P, Rademaker M, Havill J, Pullon H (1997) Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony simulating factor. Clin Exp Dermatol 22:146–147

    Article  PubMed  CAS  Google Scholar 

  10. Magina S, Lisboa C, Goncalves E, Conceicao P, Leal U, Mesquita-Guimaraes J (2000) A case of toxic epidermal necrolysis treated with intravenous immunoglobulin. Br J Dermatol 142:177–178

    Article  PubMed  Google Scholar 

  11. Mockenhaupt M, Norgauer J (2002) Cutaneous adverse drug reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergy Clin Immunol Int 14:143–150

    Article  Google Scholar 

  12. Murdoch SR, Fenton DA (1997) Toxic epidermal necrolysis and cyclosporin. Clin Exp Dermatol 22:250–256

    Article  PubMed  Google Scholar 

  13. Paquet P, Arrese Estrada J, Piérard GE (1992) Oral cyclosporin and alopecia aerata. Dermatology 105:314–315

    Article  Google Scholar 

  14. Paquet P, Jacob E, Damas P, Piérard GE (2001) Treatment of drug-induced toxic epidermal necrolysis (Lyell’s syndrome) with intravenous human immunoglobulins. Burns 27:652–655

    Article  PubMed  CAS  Google Scholar 

  15. Paquet P, Piérard GE (1999) Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis? Dermatology 198:198–202

    Article  PubMed  CAS  Google Scholar 

  16. Paquet P, Piérard GE (2002) Differential patomechanisms of epidermal necrolytic blistering diseases. Int J Mol Med 10:695–699

    PubMed  Google Scholar 

  17. Paquet P, Piérard GE (2002) Keratinocyte injury in drug-induced toxic epidermal necrolysis: simultaneous but distinct topographic expression of CD95R and calprotectin. Int J Mol Med 10:145–147

    PubMed  Google Scholar 

  18. Paquet P, Piérard GE, Quatresooz P (2005) Novel treatments for drug-induced toxic epidermal necrolysis (Lyell’s syndrome). Int Arch Allergy Immunol 136:205–216

    Article  PubMed  CAS  Google Scholar 

  19. Phan TG, Wang R, Crotty T, Adelstein S (1999) Toxic epidermal necrolysis treated with intravenous gammaglobulin. Australas J Dermatol 40:153–157

    Article  PubMed  CAS  Google Scholar 

  20. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I et al (2003) Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins. Arch Dermatol 139:26–32

    Article  PubMed  CAS  Google Scholar 

  21. Renfro L, Grant-Kels J, Daman LA (1989) Drug-induced toxic epidermal necrolysis treated with cyclosporin. Int J Dermatol 28:441–444

    Article  PubMed  CAS  Google Scholar 

  22. Roujeau JC, Guillaume JC, Fabre JP, Penso D, Flechet ML, Girre JP (1990) Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981–1985. Arch Dermatol 126:37–42

    Article  PubMed  CAS  Google Scholar 

  23. Sanclemente G, De la Roche C, Escobar C, Fabella R (1998) Pentoxifylline in toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol 38:873–874

    Google Scholar 

  24. Stella M, Cassano P, Bollero D, Clemente A, Giorio G (2001) Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 203:45–49

    Article  PubMed  CAS  Google Scholar 

  25. Sullivan JR, Watson A (1996) Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Australas J Dermatol 37:208–212

    Article  PubMed  CAS  Google Scholar 

  26. Szepietowki J, Wasik F, Szybejko-Machay G, May J (1997) Toxic epidermal necrolysis successfully treated with cyclosporin. Report of three cases. J Eur Acad Dermatol Venereol 9:169–172

    Article  Google Scholar 

  27. Trautmann A, Akdis M, Schmid-Grendelmeier P, Disch R, Bröcker EB, Blaser K et al (2001) Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol 108:839–846

    Article  PubMed  CAS  Google Scholar 

  28. Trent JT, Kirsner RS, Romanelli P, Kerdel FA (2003) Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN. Arch Dermatol 139:39–43

    Article  PubMed  CAS  Google Scholar 

  29. Tristani-Firouzi P, Petersen M, Saffle JR, Morris SE, Zone JJ (2002) Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 47:548–552

    Article  PubMed  Google Scholar 

  30. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D et al (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490–493

    Article  PubMed  CAS  Google Scholar 

  31. Wolkenstein P, Latarjet P, Roujeau JC (1998) Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 352:1586–1589

    Article  PubMed  CAS  Google Scholar 

  32. Zaki I, Patel S, Reed R, Dalziel KL (1995) Toxic epidermal necrolysis associated with severe hypocalcaemia, and treated with cyclosporin. Br J Dermatol 133:337–338

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the “Fonds d’Investissement de la Recherche Scientifique” of the University Hospital of Liège

Author information

Authors and Affiliations

  1. Department of Dermatopathology, University Hospital of Liège, CHU Sart Tilman, 4000, Liege, Belgium

    Philippe Paquet & Gérald Piérard

  2. Intensive care medicine, burn center, University Hospital of Liège, 4000, Liege, Belgium

    Eric Jacob & Pierre Damas

  3. Intensive care medicine, burn center, Brussels Military Hospital, 1120, Brussels, Belgium

    Jean Pirson

Authors
  1. Philippe Paquet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric Jacob
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierre Damas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jean Pirson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gérald Piérard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philippe Paquet.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paquet, P., Jacob, E., Damas, P. et al. Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis. Arch Dermatol Res 297, 266–273 (2005). https://doi.org/10.1007/s00403-005-0607-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-005-0607-3

Keywords

Search

Navigation